Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

US pharmacy chain Rite Aid agrees to bankruptcy mediation, gets loan approval

Published 12/19/2023, 06:14 PM
Updated 12/19/2023, 06:26 PM
© Reuters. FILE PHOTO: A woman shops inside of a Rite Aid store underneath a DeepCam security camera in New York City, New York, U.S., June 25, 2020. Picture taken June 25, 2020. REUTERS/Lucas Jackson/File Photo

By Dietrich Knauth

NEW YORK (Reuters) - Pharmacy chain Rite Aid (NYSE:US90274J5618=UBSS) received court approval on Tuesday for a bankruptcy loan that would let the company borrow an additional $200 million, while agreeing to enter mediation with committees representing junior creditors and people who have accused the company of contributing to the U.S. opioid epidemic.

Rite Aid's bankruptcy financing, which the company valued at $3.45 billion due to its refinancing of pre-existing debts, had been opposed by the U.S. government, Rite Aid's creditors committee, and a committee representing plaintiffs suing the company, including those with opioid-related claims.

Those committees have argued that Rite Aid's lenders are the only group that stands to benefit from the company's restructuring, and that victims impacted by the opioid crisis currently stand to get next to nothing out of the bankruptcy. They withdrew their objections after Rite Aid promised to mediate their concerns in January.

Rite Aid, which operates about 2,000 retail pharmacies in 17 U.S. states, filed for bankruptcy protection on Oct. 15, seeking to close underperforming stores, sell its pharmacy benefit company Elixir and resolve over 1,600 lawsuits alleging it fueled the opioid epidemic by filling illegal or suspicious prescriptions.

Rite Aid competitors Walgreens, Walmart (NYSE:WMT) and CVS have agreed to pay $13.8 billion to settle a wave of similar opioid lawsuits outside of bankruptcy.

U.S. Bankruptcy Judge Michael Kaplan at a hearing in Trenton, New Jersey, said he would approve the financing after he had time to review Rite Aid's last-minute revisions to the agreements. Some of those revisions addressed Justice Department (DOJ) concerns about legal terms that could have interfered with government oversight of Elixir, Kaplan said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The judge said earlier versions of the loan agreements contained "somewhat aggressive provisions" that understandably raised concerns about DOJ's authority to seize cash from Elixir as part of an ongoing investigation into the company's receipt of potential overpayments from the government Medicare health program.

Rite Aid's revised loan documents make clear that the company is not standing in the way of DOJ's law enforcement authority, Kaplan said, except to the extent that it asked DOJ to provide 10 days notice of any regulatory action or property seizure from Elixir.

Kaplan agreed to require DOJ to provide 10 days notice before any action that would impact Rite Aid's bankruptcy, a step that would let the company focus on its restructuring efforts, without limiting government oversight authority.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.